Medical sector’s Zynerba Pharmaceuticals’s (NASDAQ:ZYNE) Buy rating Reiterated by LADENBURG THALM/SH SH

0
26
Business Trends Graphs and charts 3d image Reference Earth Map taken from open source: http://visibleearth.nasa.gov/view_rec.php?vev1id=11656 Software used: 3dsMax Date of creation (rendered) - 26.08.2011 All layers used

Zynerba Pharmaceuticals (NASDAQ:ZYNE)‘s stock had its Buy rating Reiterated by analysts at LADENBURG THALM/SH SH in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 163.2M and a beta of 3.12.  Zynerba Pharmaceuticals has a twelve month low $2.55 of  and a twelve month high of $15.70.

Shares of Zynerba Pharmaceuticals traded up $0.24 on Monday, reaching $6.54. 4943760 shares of the stock traded hands, compared to its average volume of 1799955. Shares of Zynerba Pharmaceuticals at end of the day on Monday were at $6.54. The firm’s 50 day moving average is $5.01 and its 200 day moving average is 5.64.Zynerba Pharmaceuticals  has a 12 month low of $6.35 and a 12 month high of $15.70. While on yearly highs and lows, Zynerba Pharmaceuticals’s today has traded high as $7.45 and has touched $6.35 on the downward trend. See More Analyst Rating at: RATING

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Moving Average Technical Analysis

5 day Moving Average is 6.46 And 5 day price change is 0.86 (0.1359)  with average volume for 5 day average is 2,496,084. While technical analysis for average 20 days shows significant difference, 20 day moving average is  5.75 and 20 day price change is 1.67 (0.3026) and average 20 day moving volume is 1,929,651. 50 day moving average is 5.01  and 50 day price change is 3.18 ( 0.793)  and with average volume for 50 days is : 1,461,024. 200 day moving average is 5.64  and 200 day price change is -4.96 (-40.82%)  and with average volume for 200 days is : 834,690.

See More Analyst Rating at: RATING

Zynerba Pharmaceuticals Earnings and What to expect: 

Zynerba Pharmaceuticals last posted its earnings data on May 11th, 2020. The reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.03. Zynerba Pharmaceuticals has generated ($1.50) earnings per share over the last year. Zynerba Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 4th, 2020 based off prior year’s report dates.

Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($1.30) per share. The P/E ratio of Zynerba Pharmaceuticals is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Zynerba Pharmaceuticals is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Zynerba Pharmaceuticals has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 11.10%
  • On 8/22/2018 Director John P Butler Buy 5,000 at average share price of $6.43 which equates to $32,150.00 in money value.
  • On 8/6/2018 Chairman Armando Anido Buy 15,000 at average price of  $5.96 with total value of : Not Data Available
  • On 8/6/2018 CFO James E Fickenscher Buy 8,518 at average price of  $5.97 with total value of : $50,852.46

What other brokers have to say about Zynerba Pharmaceuticals :

  • 5/30/2020 – Zynerba Pharmaceuticals had its “buy” rating re-affirmed by analysts at Zacks Investment Research. They now have a $6.25 price target on the stock. ()
  • 5/28/2020 – Zynerba Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $21.00 to $24.00. They now have an “overweight” rating on the stock. ()
  • 5/23/2020 – Zynerba Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.50 price target on the stock. ()
  • 5/22/2020 – Zynerba Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $21.00. They now have an “overweight” rating on the stock. ()

Other firm’s rating by LADENBURG THALM/SH SH:

  • 6/26/2020 – Windtree Therapeutics is now covered by analysts at LADENBURG THALM/SH SH. They set a “buy” rating and a $12.25 price target on the stock. ()
  • 6/26/2020 – IZEA Worldwide was upgraded by analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating. ()
  • 6/23/2020 – Innovative Industrial Properties had its price target raised by analysts at LADENBURG THALM/SH SH from $83.50 to $104.00. They now have a “buy” rating on the stock. ()
  • 6/22/2020 – Cyclerion Therapeutics is now covered by analysts at LADENBURG THALM/SH SH. They set a “buy” rating on the stock. ()

See More Analyst Rating at: RATING